VISIBLE 1 clinical trial of vedolizumab to treat ulcerative colitis meets primary endpoint


  1. VISIBLE 1 clinical trial of vedolizumab to treat ulcerative colitis meets primary endpoint  News-Medical.net
  2. New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in …  BioSpace (press release) (blog)
  3. Success for Takeda in trial testing subcutaneous version of vedolizumab  The Pharma Letter
  4. Full coverage



Source link

Leave a Reply

Your email address will not be published.